sabato, 5 dicembre 2020
9 Novembre 2018

FDA Grants Selinexor Fast Track Designation for Relapsed/Refractory DLBCL

November 7, 2018 – The FDA has granted a fast track designation to selinexor for the treatment of patients with previously treated diffuse large B-cell lymphoma (DLBCL) who are ineligible to receive high-dose chemotherapy with stem cell rescue or chimeric antigen receptor (CAR) T-cell therapy, according to Karyopharm Therapeutics, Inc., the manufacturer of the first-in-class SINE compound. The designation is based on data from the multicenter, open-label, phase IIb … (leggi tutto)